Logo Logo Logo
  • Company


    • Company Overview


    • Board of Directors


    • Executive Team


    • Advisory Board
  • Pipeline


    • Product Overview


    • AR-301 (Salvecin®)


    • AR-105 (Aerucin®)


    • AR-101 (Aerumab™)


    • AR-501 (Panaecin™)


    • AR-701 (COVID-19 mAb)

    • Preclinical


      • AR-401

    • Out-licensed Products


      • AR-105 (Aerucin®)


      • AR-201
  • TECHNOLOGY


    • Technology Overview


    • APEXTM


    • MabIgX®


    • Therapeutic Targets


      • HAP / VAP


      • Cystic Fibrosis


      • AR-701 (COVID-19 mAb)
  • Investors
    • Welcome
    • Corporate Governance
      • Board of Directors
      • Board Committees
    • News Releases
    • SEC Filings
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
      • Analyst Coverage
    • Events and Webcasts
    • Publications and Posters
    • Investor alerts
    • Investor Inquiries
  • Contact Us


    • Contact Us


    • Employment
  • Company


    • Company Overview


    • Board of Directors


    • Executive Team


    • Advisory Board
  • Pipeline


    • Product Overview


    • AR-301 (Salvecin®)


    • AR-105 (Aerucin®)


    • AR-101 (Aerumab™)


    • AR-501 (Panaecin™)

    • Preclinical



      • AR-401
  • TECHNOLOGY


    • Overview


    • MabIgX®


    • Therapeutic Targets



      • HAP / VAP


      • Cystic Fibrosis
  • Investors
    • Welcome
    • Corporate Governance
      • Board of Directors
      • Board Committees
    • News Releases
    • SEC Filings
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
      • Analyst Coverage
    • Events and Webcasts
    • Publications and Posters
    • Investor alerts
    • Investor Inquiries
  • Contact Us


    • Contact Us


    • Employment
Search:
 



Investors

Aridis Pharmaceuticals
YearTrailing 12-MonthsCalendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2016Calendar Year 2015Calendar Year 2014
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Jul 2, 2019Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in HTML.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in DOC file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in PDF file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in XLS file.

CONTACT US

Aridis Pharmaceuticals Inc.
5941 Optical Court
San Jose, CA 95138
Phone: 408-385-1742
Fax: 408-960-3822

 

ADDITIONAL INFORMATION

Site Map
Privacy Policy
Financial Conflict of Interest Policy